Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Total Liabilities (2023 - 2025)

Historic Total Liabilities for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $19.3 million.

  • Zhengye Biotechnology Holding's Total Liabilities changed N/A to $19.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $19.3 million, marking a year-over-year change of. This contributed to the annual value of $19.6 million for FY2024, which is 1383.91% down from last year.
  • As of Q2 2025, Zhengye Biotechnology Holding's Total Liabilities stood at $19.3 million.
  • In the past 5 years, Zhengye Biotechnology Holding's Total Liabilities registered a high of $22.3 million during Q4 2023, and its lowest value of $19.3 million during Q2 2025.
  • Its 3-year average for Total Liabilities is $20.4 million, with a median of $19.6 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Zhengye Biotechnology Holding's Total Liabilities was 1218.83% (2024), while the steepest drop was 1218.83% (2024).
  • Quarter analysis of 3 years shows Zhengye Biotechnology Holding's Total Liabilities stood at $22.3 million in 2023, then dropped by 12.19% to $19.6 million in 2024, then fell by 1.52% to $19.3 million in 2025.
  • Its Total Liabilities was $19.3 million in Q2 2025, compared to $19.6 million in Q4 2024 and $22.3 million in Q4 2023.